Arkolith/Insider Trading/SABS/Form 4

Sessa Capital GP, LLC

DirectorSAB Biotherapeutics, Inc. (SABS) · full profile →Form 4 · filed Oct 1, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 29, 2025Option exercise(M)1.7M$1.75$3.0M2.2M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 29, 2025Option exercise(M)17K——211K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001012975-25-000592) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML